Drugs in Dev. Oncology
Phase I
Singapore 
EDDC Granted FDA Fast Track for ADC EBC-129 to Treat Pancreatic Adenocarcinoma
Details : EBC-129 is a first-in-class ADC targeting a novel, tumour-specific N256-glycosylated epitope on CEACAM5 and CEACAM6 for treating pancreatic ductal carcinoma.
Product Name : EBC-129
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
May 28, 2025
CytoMed Signs Collaboration with SunAct for Gamma Delta T Cells in Cancer
Details : The collaboration aims to advance use of allogeneic off-the-shelf Gamma Delta T Cells, CTM-N2D therapy, for treatment of solid cancers in a proposed Phase 2 clinical trial in India.
Product Name : CTM-N2D
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
January 06, 2025
CytoMed Begins Phase I CAR-Gamma Delta T Cell Therapy Trial in Solid Tumors & Malignancies
Details : CTM-N2D is being evaluated in a clinical trial that tests allogeneic NKG2DL-targeting CAR gamma delta T cells in patients with advanced solid tumors or hematological malignancies.
Product Name : CTM-N2D
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
November 20, 2024
Biosyngen’s BRG01 Enters Phase II Trial as First Autologous EBV-Specific CAR-T Therapy
Details : BRG01 is the world's first CAR-T therapy, which is being evaluated in the arly-stage clinical trial for the treatment of patients with recurrent or metastatic EBV-positive nasopharyngeal carcinoma.
Product Name : BRG01
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
July 16, 2024
Biosyngen Announces FDA Fast Track Designation for BST02 in Treatment of Liver Cancer
Details : BST02 is a tumor-infiltrating lymphocyte therapy using a patient's immune cells, evaluated in phase 1 trials for all types of liver cancer, including hepatocellular carcinoma and cholangiocarcinoma.
Product Name : BST02
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
January 02, 2024
Details : Under terms of the CRADA, Tessa will collaborate with the NCI’s DCTD to identify potential opportunities to expand the applicability of TT11X, Tessa’s allogeneic off-the-shelf CD30.CAR-modified EBVST cell therapy, as a treatment of non-Hodgkin lympho...
Product Name : TT11X
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
August 03, 2023
Lead Product(s) : TT11X,Fludarabine Phosphate,Nivolumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TT11 is an autologous CD30 chimeric antigen receptor T-cell (CAR-T) therapy that harvests the patient’s own T-cells and modifies them to target cancer cells expressing the CD30 protein, a well-validated lymphoma target.
Product Name : TT11X
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
June 16, 2023
Lead Product(s) : TT11X,Fludarabine Phosphate,Nivolumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CytoMed Therapeutics Limited Announces Pricing of Initial Public Offering
Details : The net proceeds from the initial public offering will be used to advance the clinical development of the Company's CTM-N2D product candidate and to continue technology development of the Company's iPSC-gdNKT product candidate.
Product Name : CTM-N2D
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
April 13, 2023
AUM Biosciences Identifies Asymchem as the CDMO Partner of Choice for their Novel TRK inhibitor
Details : Under the terms of the agreement, AUM and Asymchem agree to collaborate on the process development, and the clinical and commercial production, of AUM 601, which is a highly selective oral small-molecule inhibitor of the tropomyosin receptor kinase for t...
Product Name : AUM601
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 01, 2022
Lead Product(s) : AUM001,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Mountain Crest Acquisition Corp. V
Deal Size : Undisclosed
Deal Type : Merger
Details : AUM001 is a selective and synergistic MNK inhibitor as shown in current studies and expected to begin Phase 2 enrollment in the fourth quarter 2022. AUM601 is a promising therapy for TRK fusions and mutations within the kinase domain and is on track to e...
Product Name : AUM001
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 20, 2022
Lead Product(s) : AUM001,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Mountain Crest Acquisition Corp. V
Deal Size : Undisclosed
Deal Type : Merger
Reset All
